Biotech News

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Adaptive Biotechnologies (ADPT)Adaptive Biotechnologies2026-06-15 20:10 ESTCompany update

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Stock data

Close: 23.60 USD
Market cap: 2.42B USD
Exchange: NASDAQ
Sector: MedTech
Location: United States

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Related news

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

Adaptive Biotechnologies

Recent company news

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Stock data